Literature DB >> 29899079

Hormone Therapy and Breast Cancer: Emerging Steroid Receptor Mechanisms.

Meghan S Perkins1, Renate Louw-du Toit1, Donita Africander1.   

Abstract

Although hormone therapy is widely used by millions of women to relieve symptoms of menopause, it has been associated with several side-effects such as coronary heart disease, stroke and increased invasive breast cancer risk. These side-effects have caused many women to seek alternatives to conventional hormone therapy, including the controversial custom-compounded bioidentical hormone therapy suggested to not increase breast cancer risk. Historically estrogens and the estrogen receptor were considered the principal factors promoting breast cancer development and progression, however, a role for other members of the steroid receptor family in breast cancer pathogenesis is now evident, with emerging studies revealing an interplay between some steroid receptors. In this review, we discuss examples of hormone therapy used for the relief of menopausal symptoms, highlighting the distinction between conventional hormone therapy and custom-compounded bioidentical hormone therapy. Moreover, we highlight the fact that not all hormones have been evaluated for an association with increased breast cancer risk. We also summarize the current knowledge regarding the role of steroid receptors in mediating the carcinogenic effects of hormones used in menopausal hormone therapy, with special emphasis on the influence of the interplay or crosstalk between steroid receptors. Unraveling the intertwined nature of steroid hormone receptor signaling pathways in breast cancer biology is of utmost importance, considering that breast cancer is the most prevalent cancer among women worldwide. Moreover, understanding these mechanisms may reveal novel prevention or treatment options, and lead to the development of new hormone therapies that does not cause increased breast cancer risk.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29899079     DOI: 10.1530/JME-18-0094

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  5 in total

Review 1.  Treatment Progress in Diminished Ovarian Reserve: Western and Chinese Medicine.

Authors:  Qiao-Li Zhang; Ya-Ling Lei; Yan Deng; Rui-Lin Ma; Xue-Song Ding; Wei Xue; Ai-Jun Sun
Journal:  Chin J Integr Med       Date:  2022-01-11       Impact factor: 1.978

Review 2.  Bone-Muscle Crosstalk: Musculoskeletal Complications of Chemotherapy.

Authors:  Brian A Hain; David L Waning
Journal:  Curr Osteoporos Rep       Date:  2022-09-10       Impact factor: 5.163

3.  Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis.

Authors:  Xiaojing Liu; Jing Yue; Ruqiya Pervaiz; Hanwang Zhang; Lan Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-13       Impact factor: 6.055

4.  Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha.

Authors:  Meghan S Perkins; Renate Louw-du Toit; Hayley Jackson; Mishkah Simons; Donita Africander
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

5.  Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study.

Authors:  Christopher Godina; Somayeh Khazaei; Helga Tryggvadottir; Edward Visse; Björn Nodin; Karin Jirström; Signe Borgquist; Ana Bosch; Karolin Isaksson; Helena Jernström
Journal:  Carcinogenesis       Date:  2021-11-12       Impact factor: 4.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.